Mar 21, 2007 by Brian LawlerAcadia AscendingShares of Acadia more than double after a positive phase 2 trial.
Mar 21, 2007 by Brian LawlerNew Indication for PainPain Therapeutics brings a new drug into the clinic
Mar 21, 2007 by Brian LawlerInterMune Slims DownInterMune announces changes after its lead compound fails in a study.
Mar 20, 2007 by Brian LawlerSmart Move by Abbott?Abbott takes a drastic measure to make a point about its patents.
Mar 20, 2007 by Brian LawlerHeart Attack at AtheroGenicsShares of AtheroGenics drop after negative phase 3 trial results.
Mar 20, 2007 by Brian LawlerA Slowdown at EndoThe FDA delays a decision on expanding the label for one of Endo's drugs.
Mar 19, 2007 by Brian LawlerTrimeris Gets TrimmedShares of Trimeris are down after a management shakeup.
Mar 19, 2007 by Brian LawlerIs Dendreon Doomed?A pivotal FDA regulatory meeting approaches for Dendreon.
Mar 16, 2007 by Brian LawlerSelect Comfort vs. Gilead Sciences: Gilead SciencesWhy Gilead should go all the way.
Mar 16, 2007 by Brian LawlerPDL's Friend Comes ThroughPDL and partner Biogen advance one of their lead drug candidates.
Mar 15, 2007 by Brian LawlerAdolor's New PlanAdolor updates investors on its plans for its lead drug program.
Mar 15, 2007 by Brian LawlerDueling Fools: Elan BearHow do you bring an Elan bear out of hibernation?
Mar 15, 2007 by Brian LawlerIt's All Good for DrugmakersSales of prescription drugs are expected to grow rapidly over the next several years.
Mar 15, 2007 by Brian LawlerDueling Fools: Elan Bear RebuttalWith so many risks and unknowns embedded in Tysabri, I'm not convinced Elan can provide a miracle.
Mar 12, 2007 by Brian LawlerEncysive Sings the BluesEncysive announces a slower-than-expected launch of its lead drug.
